FDA approves Spravato as standalone treatment for resistant depression
A significant milestone has been reached in the fight against treatment-resistant depression. The U.S. Food and Drug Administration (FDA) recently approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for individuals who have not responded to other treatments or are unable to take oral antidepressants. Previously, Spravato was FDA-approved as an add-on … Read more